Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.2%

5 terminated/withdrawn out of 119 trials

Success Rate

94.8%

+8.3% vs industry average

Late-Stage Pipeline

32%

38 trials in Phase 3/4

Results Transparency

3 of 91 completed trials have results

Key Signals

11 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

56(50.9%)

Phase 4

26(23.6%)

Phase 2

14(12.7%)

Phase 3

12(10.9%)

N/A

2(1.8%)

110Total

Phase 1(56)

Phase 4(26)

Phase 2(14)

Phase 3(12)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (119)

Showing 20 of 119 trials

NCT07415551Phase 2Recruiting

Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines

Role: lead

NCT07470125Phase 1Not Yet Recruiting

Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers

Role: lead

NCT07359105Not ApplicableRecruiting

Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)

Role: collaborator

NCT05523947Phase 1Recruiting

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

Role: lead

NCT06041529Phase 4Active Not Recruiting

Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

Role: lead

NCT07111468Phase 3Completed

Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis

Role: lead

NCT05579626Phase 4Enrolling By Invitation

Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus (PROVE-DM)

Role: collaborator

NCT06874894Enrolling By Invitation

Thromboembolic And Bleeding Risks During anticoaGulant trEatment in Asian paTients With Atrial Fibrillation (TARGET-AF)

Role: collaborator

NCT07265167Phase 1Completed

Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects

Role: lead

NCT06517914Phase 1Recruiting

A First-in-Human, Single- and Multiple-Ascending Dose Study of YH35995 in Healthy Adult Male Participants

Role: lead

NCT06616766Phase 1Recruiting

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946

Role: lead

NCT06767345Phase 4Recruiting

Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization

Role: collaborator

NCT06975410Phase 1Recruiting

Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

Role: lead

NCT06920719Phase 1Completed

Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects

Role: lead

NCT06625931Phase 3Completed

Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition

Role: lead

NCT06926387Phase 1Completed

Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects

Role: lead

NCT04075396Phase 1Completed

A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Role: collaborator

NCT04846673Phase 4Completed

Pregabalin and Alpha-lipoic Acid Combination Versus Each Monotherapy in Patients With Diabetic Peripheral Neuropathy

Role: lead

NCT03046992Phase 1Completed

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Role: lead

NCT06775522Phase 1Completed

Bioequivalence (BE) Study Between YHP2205 and YHR2401 in Healthy Volunteers

Role: lead